Concurrent Cetuximab Is Associated With Decreased Overall Survival In Patients With Locally Advanced Head And Neck Cancer Receiving Definitive Radiotherapy: A National Cancer Database Analysis

To compare the overall survival (OS) of patients with locally advanced head and neck squamous cell carcinoma (SCC) treated with definitive radiotherapy alone (RTonly), concurrent chemoradiotherapy (chemoRT) and concurrent immunotherapy/cetuximab and radiotherapy (cetuxRT). Patients with stage III-IVB SCC of the oropharynx, larynx or hypopharynx treated with RTonly, chemoRT or cetuxRT to a definitive radiotherapy dose of 55-75 Gy were identified...